Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -0.40% | -.--% |
06-08 | US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 | RE |
06-07 | GSK says FDA Approves Expanded Age Indication For Arexvy, RSV Vaccine For Adults Aged 50-59 At Increased Risk | RE |
- Stock Market
- Equities
- GSK Stock
- GSK Stock
- News GlaxoSmithKline plc
- Other languages